Kala-azar is a deadly parasitic fever, and India aims to eliminate it with early diagnosis and treatment, but PKDL—a skin condition in cured patients—acts as a silent reservoir, spreading the parasite again. As a pharma executive, I see miltefosine as the key oral drug for both, but the real struggle is ensuring supply reaches the last village, not just the city hospitals. My team surveys show distributors hesitate to stock it in Bihar's endemic zones, thinking profits lie in metro chronic illness drugs instead. This blind spot in the supply chain, ji, is what truly keeps the disease alive.
#athletics#track-and-field
Jump in to reply — no account needed.